TWM636071U - Sun contact lenses for myopia therapy - Google Patents

Abstract

A solar contact lens for treating myopia, comprising: an arc-shaped contact lens and several nanoparticles evenly distributed on the contact lens; a myopia treatment agent loaded on the nanoparticle; and the contact lens It has the ability to block at least part of ultraviolet light with a wavelength of 400nm and visible light with a wavelength of 400nm~700nm; the new type can release the myopia treatment agent slowly and for a long time through the aforementioned nanoparticle-loaded treatment agent for myopia and can efficiently block all The effect of ultraviolet rays and part of visible light is used to improve the problems of photophobia after using mydriatics in the existing technology, and various problems that affect the convenience of activities when wearing sunglasses.

Description

Sun contact lenses for myopia

A contact lens, in particular a solar contact lens with the function of treating myopia and improving photophobia.

Mydriatic agent is a kind of cycloplegic drug, commonly used in the treatment of myopia. Its function is to dilate and paralyze the pupil, relax the ciliary muscle, and make the pseudomyopia caused by the tight ciliary muscle return to normal, or control the myopia that is already myopic. The ciliary muscles do not continue to tighten.

At the same time of treatment, after the use of mydriatics, the pupils will continue to dilate and cannot shrink with the intensity of the light, resulting in more light entering the eyes, so it is often accompanied by side effects of photophobia. If you do not wear sunglasses for protection, you may also suffer from Cause macular degeneration or cataracts.

However, wearing sunglasses for a long time not only affects normal activities and rest, but also may affect the appearance of the appearance. Therefore, there is an urgent need for a method that can simultaneously use mydriatics to treat myopia and avoid photophobia, and has both wearing convenience and aesthetics. sexual products.

In order to improve the problem of photophobia after using mydriatics, and wearing sunglasses affects the convenience of activities, the present invention provides a first kind of solar contact lens for treating myopia, which includes: a contact lens of arc disc type and Several nanoparticles are evenly distributed on the contact lens; A medicine for treating myopia is loaded on the nanoparticles; and the contact lens has the ability to block at least part of ultraviolet light with a wavelength of 400nm and visible light with a wavelength of 400nm-700nm.

The present invention also provides another kind of solar contact lens for treating myopia, which comprises: two contact lenses of arc-disc shape, sandwiching the same disc-shaped nanoparticles formed by several nanoparticles to form a sandwich structure Similarly, the solar contact lens for the treatment of myopia provided in this embodiment also includes the myopia treatment agent loaded on the nanoparticles; of visible light.

Wherein, the aforementioned nanoparticles have several mesoporous holes with different pore diameters.

Wherein, the aforementioned structure of the nanoparticles includes a plurality of sheet-like overlapping structures extending from the particle center to the four directions, and the mesoporous holes with different pore diameters are distributed on the sheet-like overlapping structures or from the particles. The center extends a plurality of dendritic protruding structures in all directions, and the mesoporous holes with different apertures are distributed on the dendritic structures.

Wherein, the aforementioned nanoparticles have an active functional group on the surface, so that the myopia treatment agent can be stably loaded on the nanoparticles.

Wherein, the distribution of the aforementioned nanoparticles does not protrude from the surface of the contact lens, but is flush with the surface of the contact lens.

Preferably, the contact lens has a color that helps to block harmful light, including see-through gray, yellowish brown or dark green.

Wherein, the specific surface area (BET Surface Area) of the nanoparticles is at least 100m ² /g, and the particle diameter is between 10~500nm; the average pore diameter of the mesoporous holes is at least 1nm, and the pore volume From 0.10 cm ³ /g to 5.0 cm ³ /g.

Preferably, the contact lens material comprises hydrogel or silicon hydrogel; the contact lens material comprises hydrogel or silicon hydrogel; the myopia treatment agent comprises a mydriatic agent, and the mydriatic agent comprises atropine (Atropine) or its derivative salts.

From the above description, it can be seen that the present invention uses the above-mentioned nanoparticle-loaded myopia treatment agent, so that the new model has a slow and long-term release of the myopia treatment agent and can efficiently block all ultraviolet rays and part of visible light. The solar contact lens for myopia treatment to improve At present, there are problems of photophobia after using mydriatics in existing technologies, and various problems that affect the convenience of activities when wearing sunglasses.

10: Contact lenses

20: Nanoparticles

21: Mesopores

30: Myopia treatment potion

40: user

41: eyeball

In order to illustrate the technical solutions of the embodiments of the present invention more clearly, the diagrams that need to be used in the description of the embodiments will be briefly introduced below. It can be understood that, unless it is specifically or indirectly deduced or otherwise stated from the context, the same symbols in the drawings represent the same or similar structures. The drawings provided by the present invention are only some examples or embodiments of the present invention. For those with ordinary knowledge in the field, the present invention can also be applied to other similar use. Wherein: Fig. 1 is the schematic diagram of the first preferred embodiment of the sun contact lens for treating myopia of the present invention.

Fig. 1A is a partially enlarged cross-sectional view of the schematic diagram of the first preferred embodiment.

Fig. 2 is a schematic diagram of a second preferred embodiment of the new solar contact lens for treating myopia.

Fig. 3 is the use schematic diagram and action diagram of the new solar contact lens for treating myopia.

As shown in the present invention, words such as "a", "an", "an" and/or "the" are not specific to the singular and may include the plural, unless the context clearly suggests an exception. Generally speaking, the terms "comprising" and "comprising" only suggest the inclusion of clearly identified steps and elements, and these steps and elements do not constitute an exclusive list, and the method or device may also contain other steps or elements. "System", "device", "unit" and/or "module" as used in the present invention below is a method for distinguishing different components, elements, parts, parts or assemblies of different levels. However, the words may be replaced by other expressions if other words can achieve the same purpose.

< The first preferred embodiment of the sun contact lens for treating myopia >

Please refer to FIG. 1 , which is a schematic diagram of a first preferred embodiment of the new solar contact lens for treating myopia, which includes a contact lens 10 in the shape of an arc disc, and several nanoparticles 20 are evenly distributed in the contact lens 10 superior. The aforementioned so-called arc disc shape is preferably an arc disc shape corresponding to the arc surface of the human eyeball.

Wherein, the appearance of the nanoparticles 20 presents several mesopores 21 with different pore diameters, the specific surface area (BET Surface Area) of the nanoparticles 20 is at least 100 m ² /g, and the average pore size of the mesopores 21 (Average pore diameter) may be at least 1 nm or more, the pore volume (pore volume, Pore Volume) is 0.10 cm ³ /g or more to 5.0 cm ³ /g and the particle diameter (Particle diameter) is between 10-500 nm. Wherein, the aforementioned average pore diameter (Average pore diameter) is more preferably above 2nm, and may be below 50nm; the specific surface area is more preferably above 300m ² /g, more preferably above 600m ² /g, more preferably 800m ² /g or more; the pore size is more preferably 3nm or more, more preferably 10nm or more, more preferably 20nm or more, preferably a small pore diameter of 3nm to a large pore diameter of 50nm; the pore volume is further preferably 0.5cm ³ /g More than 5.0cm ³ /g, more preferably 1.0cm ³ /g or more to 5.0cm ³ /g, more preferably 1.5cm ³ /g or more to 5.0cm ³ /g; the particle size is still more preferably 60~150nm .

The structure of the nanoparticles 20 of the present invention may include multiple sheet-like overlapping structures extending from the center of the particle to the four directions, and the mesoporous holes 21 with different apertures are distributed on the sheet-like overlapping structures, or the present invention The structure of the nanoparticles 20 may also include a plurality of dendritic protrusions extending from the center to four directions, and the mesoporous holes 21 with different pore sizes are distributed on the dendritic structures. The nanoparticle 21 is preferably made of silicon dioxide material and has large-pore mesoporous silicon dioxide nanoparticles (Large-pore Mesoporous silica nanoparticles, LPMSNs).

A myopia treatment agent 30 is loaded on the nanoparticles 20, preferably loaded in the mesoporous hole 21. The myopia treatment agent 30 includes a mydriatic agent, such as atropine (Atropine) or its derivative salt (Atropine sulfate salt monohydrate) . Preferably, the surface of the nanoparticles 20 has an active functional group, and the active functional group has appropriate compatibility and binding properties with the myopia treatment agent 30, so that the two can be firmly combined and make the myopia treatment agent 30 loaded on the nanoparticles 20 or in the mesoporous holes 21 . The active functional groups preferably include hydroxyl (-OH), carboxylic acid (-COOH), amine (-NH ₂ ), acrylic acid (acrylic acid, Acrylic), sulfhydryl (-SH), bis A sulfur bond (SS) or a combination of the aforementioned functional groups becomes a composite functional group.

Preferably, as shown in the enlarged partial section of Fig. 1A, the nanoparticles 20 do not protrude from the surface of the contact lens 10, but are flush with the surface of the contact lens 10 and make the sun contact lens for treating myopia of the present invention Has a smooth surface.

The material of the contact lens 10 is preferably divided into two types: hydrogel or silicon hydrogel. The contact lens 10 preferably has the function of blocking all ultraviolet rays and part of visible light. Preferably, the ultraviolet light refers to light with a wavelength of 400nm (UV400), and the contact lens 10 of the present invention can preferably block 100% of the ultraviolet light. Visible light refers to the wavelength of light 400nm~700nm light, and the contact lens 10 of the present invention preferably can block at least 60%, or at least 80%, or better 90% of visible light.

Wherein, the hydrogel formula may include hydroxyethyl methacrylate ((Hydroxyethyl) methacrylate, referred to as HEMA), ethylene glycol dimethacrylate (Ethyleneglycoldimethacrylate, referred to as EGDMA), N-vinylpyrrolidone (N-Vinylpyrrolidone) It is polymerized with at least one or several polymer monomers of polymethyl methacrylate (PMMA), and different (light or heat) initiators contain azobisisobutyronitrile (Azobisisobutyronitrile or 2,2'-Azobis (2-methylpropionitrile), AIBN for short), Phenyl-azotriphenylmethane (Phenyl-azotriphenylmethane), tert-butyl-peroxide (TBP for short), diisoperoxide Cumyl peroxide, benzoyl peroxide (BPO for short), tert-butyl perbenzoate (Tert-butyl perbenzoate, TBPB for short), etc., and the photoinitiator can be 2,4 ,6-trimethylbenzoyl-diphenylphosphine oxide (2,4,6-trimethylbenzoyldiphenyl phosphine oxide, TPO for short), 2-hydroxy-2-methyl-1-phenylacetone (2-Hydroxy- 2-Methyl-1-phenyl-1-Porpanone (HMPP for short), 1-hydroxycyclohexyl phenyl ketone (1-hydroxycyclohexyl phenyl ketone), phenyl bis(2,4,6-trimethylbenzoyl Base) phosphine oxide (Phenyl bis(2,4,6-trimethylbenzoyl)-phosphine oxide) contains at least one of the above ingredients.

The silicone hydrogel contains hydroxyethyl methacrylate (the aforementioned HEMA), methyl methacrylate (MMA for short, acrylic monomer), polydimethylsiloxane (PDMS for short) , polyethylene glycol - polydimethylsiloxane methyl acrylate (PEG-PDMS methacrylate), N-vinylpyrrolidone (N-vinylpyrrolidone), tetraethylene glycol dimethacrylate (tetra (ethylene glycol) dimethacrylate ), ethylene glycol methyl ether methacrylate (ethylene glycol methyl ether methacrylate) or azobisisobutyronitrile (Azobisisobutyronitrile or 2,2'-Azobis (2-methylpropionitrile), referred to as AIBN) contains at least one of the above ingredients.

The contact lens 10 is further not completely transparent, and may have a color that helps block harmful light, such as see-through gray, see-through tan or see-through dark green. Among them, the gray contact lens 10 can evenly block the wavelengths of various colors, and will not affect the eyes' ability to judge the color authenticity. The yellow-brown contact lens 10 can filter short-wave blue light, and can also increase contrast sensitivity and acuity, and is especially suitable for increasing visual judgment when exercising or looking at things. In addition to filtering ultraviolet rays, the green contact lens 10 can also filter infrared rays, mainly allowing light with a wavelength of 550nm that is more comfortable for the eyes to enter, thereby increasing wearing comfort.

< Second preferred embodiment of solar contact lens for treating myopia >

Please refer to FIG. 2 , which is a schematic diagram of a second preferred embodiment of the new sun contact lens for treating myopia. This embodiment comprises two said contact lenses 10. The same disk-shaped nanoparticles 20 formed by said nanoparticles 20 are interposed therein to form a sandwich structure. The overall thickness of the solar contact lens for treating myopia is about 100 μm. The technical features of the contact lens 10 and the nanoparticles 20 of the second preferred embodiment are the same as those of the first preferred embodiment, and will not be repeated here.

< Schematic diagram of the use of solar contact lenses for the treatment of myopia >

Please refer to Fig. 3, when the new model is used, it is worn and attached to the two eyeballs 41 of a user 40, and the myopia treatment agent 30 carried by the nano particles 20 on the contact lens 10 is gradually released from the nano particles. The particles 20 are released and contact the eyeball 41 to provide a long-lasting therapeutic effect on myopia. At the same time, the contact lens 10 has a sunglass-like function of blocking all ultraviolet light and part of visible light, so it can greatly improve the photophobia problem of the user 40 caused by the myopia treatment agent 30 .

Numerals describing quantities of ingredients and attributes are used in some examples, and it should be understood that such numbers used in the description of the examples use the modifier words "about", "approximately", "approximately" or "approximately" in some examples. Generally" to modify. Unless otherwise stated, "about", "approximately" or "substantially" indicates that the stated figure allows for a variation of ±20%. Accordingly, in some embodiments, the numerical parameters used in the specification and claims are approximations that may vary depending upon the desired characteristics of individual embodiments. In some embodiments, numerical parameters should take into account the specified significant digits and adopt the general digit reservation method. Although the numerical ranges and parameters used to confirm the breadth of the scope of some embodiments of the present invention are approximations, in specific embodiments, such numerical values are set as precisely as practicable.

Finally, it should be understood that the embodiments described in the present invention are only used to illustrate the principles of the embodiments of the present invention. Other deformations may also fall within the scope of the present invention. Thus, by way of illustration and not limitation, alternative configurations of the embodiments of the invention may be considered consistent with the teachings of the invention. Accordingly, the embodiments of the present invention are not limited to the embodiments of the present invention that are explicitly shown and described.

10: Contact lenses

20: Nanoparticles

21: Mesopores

30: Myopia treatment potion

Claims (12)

A sun contact lens for treating myopia, comprising: A contact lens in the shape of an arc disc and several nanoparticles evenly distributed on the contact lens; A myopia treatment agent is loaded on the nanoparticles; and The contact lens has the function of blocking at least part of ultraviolet light with a light wavelength of 400nm and visible light with a light wavelength of 400nm-700nm. A sun contact lens for treating myopia, comprising: In the arc disc-shaped two contact lenses, the same disc-shaped nanoparticles formed by several nanoparticles are sandwiched to form a sandwich structure; A myopia treatment agent is loaded on the nanoparticles; and The contact lens has the function of blocking at least part of ultraviolet light with a light wavelength of 400nm and visible light with a light wavelength of 400nm-700nm. The solar contact lens for treating myopia as described in Claim 1, wherein: the nanoparticles have several mesoporous holes with different apertures. The solar contact lens for treating myopia as described in Claim 2, wherein: the nanoparticles have several mesoporous holes with different apertures. The sun contact lens for treating myopia as described in claim 3 or 4, wherein: the structure of the nanoparticles includes a plurality of sheet-shaped overlapping structures extending from the center of the particle to the four sides, and in the sheet-like The mesoporous holes with different pore diameters are distributed on the overlapping structure. The solar contact lens for treating myopia as described in claim 3 or 4, wherein: the structure of the nanoparticle includes a plurality of dendritic protrusions extending from the center of the particle to the four directions, and distributed on the dendritic structure Different pore diameters of the mesoporous holes. The solar contact lens for treating myopia according to claim 1, 2, 3 or 4, wherein: the surface of the nanoparticles has an active functional group, so that the myopia treatment agent is firmly loaded on the nanoparticles. The solar contact lens for treating myopia as described in Claim 1, 2, 3 or 4, wherein: the distribution of the nanoparticles does not protrude from the surface of the contact lens, but is flush with the surface of the contact lens. The sun contact lens for treating myopia as described in Claim 1, 2, 3 or 4, wherein: the contact lens has a color that helps block harmful light, including see-through gray, yellowish brown or dark green. The solar contact lens for treating myopia as described in claim 1, 2, 3 or 4, wherein: the nanoparticle specific surface area (BET Surface Area) is at least 100 m ² /g or more, and the particle diameter (Particle diameter) is between at 10-500 nm. The solar contact lens for treating myopia as described in Claim 3 or 4, wherein: the average pore diameter of the mesoporous holes (Average pore diameter) is at least 1 nm, and the pore volume is 0.10 cm ³ /g or more to 5.0 cm ³ /g . The solar contact lens for treating myopia as described in claim 1, 2, 3 or 4, wherein: The contact lens material comprises hydrogel or silicon hydrogel; The nanoparticle material includes silicon dioxide nanoparticles with mesoporous holes formed by a silicon dioxide material; and The myopia treatment agent includes a mydriatic agent, and the mydriatic agent includes atropine (Atropine) or its derivative salts.

Images